Peter A. Thompson
Co-Founder & Independent DirectorDr. Peter A. Thompson, FACP., M.D., is Director of Aspen Neuroscience, Inc. from March 2020. Dr. Thompson joined the Aspen Neuroscience, Inc. in March 2020. Dr. Thompson is Director of Terremoto Biosciences, Inc. from August 2026. He is Director of Perfuse Therapeutics, Inc. He is Director of Forward Therapeutics, Inc. from December 2025. He serves as an Independent Director at ARS Pharmaceuticals Inc since April 2016. He is the Co-Founder and Scientific Advisor at Terremoto Biosciences, Inc. He serves as Director at Alpheus Medical, Inc. He has been Director at ProLynx LLC since September 2025. He serves as a Director at Sparrow Pharmaceuticals, Inc. He serves as Director of Gennao Bio, Inc. since March 2022. He has been an Independent Director at Sionna Therapeutics, Inc. since February 2022. He serves as General Partner at OrbiMed Advisors LLC since December 2021. He was a Private Equity Partner with OrbiMed Advisors LLC since 2013 until December 2021 and was its Venture Partner since joining in September 2010 to 2013. He serves as Chairman of the Board of Directors of Silverback Therapeutics, Inc. since April 2016. He is the Co-Founder of Silverback Therapeutics, Inc. He served as Chief Executive Officer of Silverback Therapeutics, Inc. from April 2016 to April 2020 and also served as its President until April 2020. He served as an Independent Director at Decibel Therapeutics, Inc. from November 2020 to June 13, 2023. He had been an Independent Director of Janux Therapeutics, Inc. since March 3, 2021 until June 14, 2023. He founded Strategicon Partners and serves as its Managing Director. He served as Director of Prevail Therapeutics Inc., since August 2017 until January 21, 2021. He Co-Founded Edgewise Therapeutics, Inc. in 2017 and serves as its Independent Chairman since August 2017 and Independent Director since May 2017. He Co-Founded Silverback Therapeutics in 2016 and serves as Chief Executive Officer and Director. He co-founded Cleave Therapeutics, Inc. in 2010. He Co-founded Corvus Pharmaceuticals, Inc., in November 2014 and has been its Independent Director since November 2014. He Co-Founded Emergent Product Development Seattle LLC and served as its President and Chief Executive Officer from May 2002 to November 16, 2009. He served as Treasurer of Emergent Product Development Seattle, LLC since December 2002. He served as the Executive Chairman of Response Biomedical Corp. since August 09, 2011, until August 2014 and its Interim Chief Executive Officer from August 9, 2011 to April 2012. He was a Venture Partner at ATP Capital from 2003 to 2006. He Co-Founded Trubion Pharmaceuticals and served as Chief Executive Officer and Chairman from 2002 to 2009. He co-founded Converge Medical, Inc. in 2002 and served as its Chief Executive Officer and President. He served as Head of R&D for BD Bioscience and Vice President and General Manager of Chiron Informatics at Chiron Corporation. He was a senior executive of Chiron Corporation from 1995 to 1999. He served as Vice President of Research and Technology development at Becton Dickinson Immunocytometry Systems. He co-founded iMetrikus Inc. and served as its Chief Executive Officer and Chairman from 1999 to 2000. He was Chairman of Principia Biopharma Inc. until September 18, 2018 and served as its Director since February 2011 until September 18, 2018. He served as Chairman of Emergent Product Development Seattle, LLC from March 2006 to November 16, 2009 and as its Director from February 2002 to November 16, 2009.He served as a Director of Synthorx, Inc. from April 2018 to January 22, 2020. He was Chairperson of Terremoto Biosciences, Inc. and was its President since August 2021 and served as its Chief Executive Officer since August 2021 until July 2024. He previously served as Chief Executive Officer and President of two private companies: Glia Biotherapeutics, Inc. from July 2018 to July 2023 and Terremoto Therapeutics Holdings, LLC from August 2021 to December 2022. He had been an Independent Director of Alpine Immune Sciences, Inc. since June 13, 2016. He serves as a Director of Cleave Therapeutics, Inc. (formerly known as Cleave Biosciences, Inc.), AllianceVista, E-Scape Bio, Inc. and Ocunexus Therapeutics, Inc. He serves as Director of ReCode Therapeutics and Aspen Neuroscience, Inc. He has been a Director of Cardioxyl Pharmaceuticals, Inc. since November 13, 2012. He was Non-Executive Director of Adaptimmune Therapeutics plc from February 2015 to July 05, 2018. He has been a Director of MethylGene Inc., since June 14, 2011. He served as an Independent Director at PMV Pharmaceuticals, Inc. since November 2014 until January 2022. He served as a Director of Nivalis Therapeutics, Inc. since July 24, 2017. He served as Director of Response Biomedical Corp. since June 2010 until January 12, 2017. He served as an Independent Director at ProNAi Therapeutics, Inc. from April 2014 to December 18, 2015. He served as a Director of Quark Pharmaceuticals, Inc. He served as a Director of Mirati Therapeutics, Inc. since June 14, 2011 until May 21, 2014. He served as Director of Anthera Pharmaceuticals, Inc. from February 1, 2011 to May 16, 2013 and of Sierra Oncology, Inc. from April 2014 to December 18, 2015. He served as a Director at Converge Medical, Inc. He was on the Board of Becton Dickinson from 1991 to 1995. He is an Affiliate Professor of Neurosurgery at the University of Washington since January 2010. He was a medical staff fellow at the National Cancer Institute from 1985 to 1992. He did internal medicine training at Yale University. He is an Ernst & Young Entrepreneur of the Year awardee. He is a Board-Certified Internist and Oncologist. He serves as Director of Recode Therapeutics; Inc. He holds a B.Sc. in Molecular Biology and Mathematics from Brown University from 1977 to 1981 and an M.D. in medicine from Brown University Medical School from 1980 to 1984.
Positions
- Company NameCorvus Pharmaceuticals, Inc.Stock CodeCRVSPositionCo-Founder & Independent DirectorColleagues
- RARichard A. MillerCo-Founder, President, CEO & Chairman of the Board
- PAPeter A. ThompsonCo-Founder & Independent Director
- LLLeiv LeaChief Financial Officer
- WBWilliam Benton JonesSenior Vice President of Pharmaceutical Development
- ZKZack KubowVice President of Investor Relations & Corporate Communications
- RARichard A. van den BroekIndependent Director
- LSLinda S. GraisIndependent Director
- DSDavid S. MooreIndependent Director
- Company NameEdgewise Therapeutics, Inc.Stock CodeEWTXPositionCo-Founder & Independent Chairman
